Compare this test’s laboratory options
Glutamic Acid Decarboxylase-65 Antibody
Access Labcorp Draw · Access Medical Labs · Quest Diagnostics3 test optionsFrom $87.51
Glutamic Acid Decarboxylase-65 Antibody
Access Labcorp Draw · Access Medical Labs · Quest DiagnosticsCatalog information reviewed: August 24, 2026 by the Sunridge Medical clinical team.
What this laboratory test evaluates
DetailsGlutamic Acid Decarboxylase-65 Antibody – Glutamic acid decarboxylase (GAD-65) antibody is useful to diagnose insulin dependent diabetes mellitus [Type I diabetes (autoimmune-mediated diabetes)] to assess risk for development of Type I diabetes, to predict onset of Type I diabetes, and risk of development of related endocrine disorders, e.g., thyroiditis. Before clinical onset, Type I diabetes is characterized by lymphocytic infiltration of the islet cells, and by circulating autoantibodies against a variety of islet cell antigens, including GAD-65, IA-2 (a tyrosine phosphatase-like protein), and insulin (IAA).
What type of sample is required for this test?1 mL serum
Test ResourcesFor more information, please consult your healthcare provider.
Additional test information
Glutamic Acid Decarboxylase-65 Antibody – Glutamic acid decarboxylase (GAD-65) antibody is useful to diagnose insulin dependent diabetes mellitus [Type I diabetes (autoimmune-mediated diabetes)] to assess risk for development of Type I diabetes, to predict onset of Type I diabetes, and risk of development of related endocrine disorders, e.g., thyroiditis. Before clinical onset, Type I diabetes is characterized by lymphocytic infiltration of the islet cells, and by circulating autoantibodies against a variety of islet cell antigens, including GAD-65, IA-2 (a tyrosine phosphatase-like protein), and insulin (IAA).
Collection and processing
- Sample type: Serum
- Fasting: No
- Estimated laboratory processing: Results should be available in 2 – 5 business days after the sample is collected
How Sunridge uses laboratory information
Sunridge considers the medical question, symptoms, history, medications, prior results, and whether the finding could change care before recommending testing. A laboratory result is not interpreted in isolation and does not establish a diagnosis by itself.
Before requesting this test
Availability, collection requirements, eligibility, and processing estimates can change. Sunridge reviews each request and, when appropriate, creates the order through Fullscript. Follow the current instructions supplied with the approved order.
Common questions about this laboratory test
- What sample does this test require?
- The listed sample type is Serum. Confirm current collection instructions in the approved order.
- Does this test require fasting?
- The current catalog record lists fasting as: No. Follow the instructions supplied with the approved order.
- How long does laboratory processing usually take?
- Results should be available in 2 – 5 business days after the sample is collected. Timing can change after collection or if a laboratory requires additional review.
About this test
DetailsGlutamic Acid Decarboxylase-65 Antibody - Glutamic acid decarboxylase (GAD-65) antibody is useful to diagnose insulin dependent diabetes mellitus [Type I diabetes (autoimmune-mediated diabetes)] to assess risk for development of Type I diabetes, to predict onset of Type I diabetes, and risk of development of related endocrine disorders, e.g., thyroiditis. Before clinical onset, Type I diabetes is characterized by lymphocytic infiltration of the islet cells, and by circulating autoantibodies against a variety of islet cell antigens, including GAD-65, IA-2 (a tyrosine phosphatase-like protein), and insulin (IAA).
What type of sample is required for this test?1 mL serum
Test ResourcesFor more information, please consult your healthcare provider.
Additional details
Glutamic Acid Decarboxylase-65 Antibody - Glutamic acid decarboxylase (GAD-65) antibody is useful to diagnose insulin dependent diabetes mellitus [Type I diabetes (autoimmune-mediated diabetes)] to assess risk for development of Type I diabetes, to predict onset of Type I diabetes, and risk of development of related endocrine disorders, e.g., thyroiditis. Before clinical onset, Type I diabetes is characterized by lymphocytic infiltration of the islet cells, and by circulating autoantibodies against a variety of islet cell antigens, including GAD-65, IA-2 (a tyrosine phosphatase-like protein), and insulin (IAA).
Highlighted health areas
- Metabolic function
- Autoimmune
Biomarkers and report focus
The exact analytes and report format can change. Confirm the current contents in the Fullscript order before payment.
- Glutamic Acid Decarboxylase-65 Antibody